Osanetant - Novel Investigational Agent for the Treatment of Schizophrenia
Key Data:
Drug (brand/generic)
Osanetant (SR-142801
Company/licensee
Sanofi-Aventis
Therapy class
Antipsychotic
Product description
NK3 receptor antagonist
Current indication
Treatment of schizophrenia
Market sector
CNS
Development status
Discontinued
